Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $16.76, but opened at $14.96. Mesoblast shares last traded at $14.69, with a volume of 112,482 shares trading hands.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on MESO. StockNews.com cut Mesoblast from a "hold" rating to a "sell" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Jefferies Financial Group upgraded shares of Mesoblast from a "hold" rating to a "buy" rating in a research note on Thursday, August 29th. Maxim Group raised shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a report on Tuesday, September 24th. Finally, Piper Sandler lifted their price target on Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $13.50.
Check Out Our Latest Research Report on Mesoblast
Mesoblast Price Performance
The stock's 50-day simple moving average is $10.48 and its 200 day simple moving average is $8.28. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.
Institutional Trading of Mesoblast
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC boosted its stake in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after purchasing an additional 26,959 shares during the period. XY Capital Ltd bought a new stake in shares of Mesoblast in the third quarter valued at about $244,000. Signaturefd LLC grew its stake in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after acquiring an additional 3,099 shares in the last quarter. Creative Planning bought a new position in Mesoblast during the third quarter worth about $147,000. Finally, Perkins Coie Trust Co raised its stake in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock worth $94,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
